Major Events - Xidi Intelligent Driving (03881) plans to conduct an IPO from December 11 to December 16, aiming to globally issue 5.408 million H-shares and has introduced cornerstone investors such as Xiangjiang Zhicheng [1] - Zhihui Mining (02546) will also hold an IPO from December 11 to December 16, with a plan to globally issue 122 million H-shares and has brought in cornerstone investors like Spico [1] - Stone Four Pharmaceutical Group (02005) has obtained the production registration approval for Acetylcysteine Injection (25ml: 5g) [1] - Yunjie (02670) intends to establish a joint venture focusing on developing robotic smart solutions for innovative scenarios [1] - Huiju Technology (02481) has introduced new investor Shuangliang Energy to accelerate the commercialization of industrial inspection robots [1] - Leap Motor (09863) received an increase in shareholding from shareholders Zhu Jiangming and Fu Liqian, totaling 2.1506 million H-shares, with an investment exceeding 100 million HKD [1] - Red Star Macalline (01528) saw shareholders Taobao Holdings and New Retail Fund collectively reduce their holdings by 30.616 million H-shares [1] - China National Nuclear Corporation (01763) subsidiary signed a patent transfer agreement for innovative nuclear medicine with Beijing Normal University [1] - ZTE Corporation (00763) is in communication with the U.S. Department of Justice regarding certain matters and will firmly protect its rights through legal means [1] - Techtronic Industries (00669) plans to voluntarily terminate its HART business by the end of the year [1] Operating Performance - China General Nuclear Power Corporation (01811) reported a cumulative power generation of 17.5 billion kWh in the first 11 months, a decrease of 1.0% year-on-year [1] - China Resources Power (00836) subsidiary's power plants reported a 7.1% year-on-year increase in electricity sales in the first 11 months [1] - Hong Kong Science and Technology Exploration (01137) reported a total merchandise transaction value of 636 million HKD in November for its electronic commerce business, a year-on-year decline of 7.4% [1]

此外，该集团已取得国家药监局有关复方醋酸钠林格注射液(500ml)的药品生产注册批件，属于化学药 品第3类，视同通过一致性评价。复方醋酸钠林格注射液主要用于循环血容量及组织间液减少时细胞外 液的补充及代谢性酸中毒的纠正。 石四药集团(02005)公布，该集团已取得中国国家药品监督管理局有关乙醯半胱氨酸注射液(25ml: 5g)的 药品生产注册批件，属于化学药品第3类，视同通过一致性评价，是国内企业第三家获批。乙醯半胱氨 酸注射液主要用于急性对乙醯氨基酚中毒解毒，预防或减轻其过量引起的肝脏损伤。 ...

石四药集团(02005)公布，该集团已取得中国国家药品监督管理局有关乙醯半胱氨酸注射液(25ml:5g)的 药品生产注册批件，属于化学药品第3类，视同通过一致性评价，是国内企业第三家获批。乙醯半胱氨 酸注射液主要用于急性对乙醯氨基酚中毒解毒，预防或减轻其过量引起的肝脏损伤。 此外，该集团已取得国家药监局有关复方醋酸钠林格注射液(500ml)的药品生产注册批件，属于化学药 品第3类，视同通过一致性评价。复方醋酸钠林格注射液主要用于循环血容量及组织间液减少时细胞外 液的补充及代谢性酸中毒的纠正。 ...

董事局亦欣然公告，集团已取得国家药监局有关复方醋酸钠林格注射液(500ml)，属於化学药品第3类， 视同通过一致性评价。复方醋酸钠林格注射液主要用于循环血容量及组织间液减少时细胞外液的补充及 代谢性酸中毒的纠正 格隆汇12月11日丨石四药集团(02005.HK)公告，集团已取得中国国家药监局有关乙醯半胱氨酸注射液 (25ml: 5g)的药品生产注册批件，属于化学药品第3类，视同通过一致性评价，是国内企业第三家获批。 乙醯半胱氨酸注射液主要用于急性对乙醯氨基酚中毒解毒，预防或减轻其过量引起的肝脏损伤。 ...